Regulation of UT-OC-3 ovarian carcinoma cells by cytokines: Inhibitory effects on cell proliferation and activation of transcription factors AP-1 and NF-κB

European Journal of Endocrinology

Volumn 142, Issue 4, 2000, Pages 393-401

  Seppänen, Marjo ^a,b   Lin, Lin ^a,b   Punnonen, Juha ^c   Grénman, Seija ^d,e   Punnonen, Reijo ^a   Vihko, Kimmo K ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c MERCK RESEARCH LABORATORIES   (United States)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CELL DNA; CYTOKINE; DEOXYURIDINE; DNA FRAGMENT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER MODEL; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; CYSTADENOCARCINOMA; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0343674088     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1420393     Document Type: Article

References (49)

1. Fathalla M. Incessant ovulation - a factor in ovarian neoplasia? Lancet 1971 2 163.
2. Schildkraut J, Bastos E & Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. Journal of the National Cancer Institute 1997 89 932-938.
3. Serov S, Scully R & Sobin L. International Classification of Tumours no 9. Histological Typing of Ovarian Tumours. Geneva: World Health Organization. 1973.
4. Merino M & Jaffe G. Age contrast in ovarian pathology. Cancer 1993 71 537-544.
5. Itri L. The interferons. Cancer 1992 70 940-945.
6. Miller A, McBride W, Hunt K & Economou J. Cytokine-mediated gene therapy for cancer. Annals of Surgical Oncology 1994 1 436-450.
7. Richters C, Burger C, van de Loosdrecht A, van Rijswijk R, Calame W, Bleker O et al. The cellular composition in the peritoneal cavity and the cytotoxic function of the peritoneal cells from patients with ovarian cancer; effect of tumour necrosis factor-α treatment. Cancer Letters 1993 68 25-31.
8. Tabibzadeh S. Cytokines and the hypothalamic-pituitary-ovarian-endometrial axis. Human Reproduction Update 1994 9 947-967.
9. Erroi A, Sironi M, Chiaffarino F. Zhen-Guo C, Mengozzi M & Mantovani A. IL-1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma. International Journal of Cancer 1989 44 795-801.
10. Moradi M, Carson L, Weinberg B, Haney A, Twiggs L & Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1. interleukin-6. and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 1993 72 2433-2440.
11. Pisa P, Halapi E, Pisa E, Gerdin E, Hising C, Buchta A et al. Selective expression of interleukin 10, interferon γ. and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proceedings of the National Academy of Sciences of the USA 1992 89 7708-7712.
12. Engblom P, Rantanen V, Kulmala J, Helenius H & Grenman S. Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. British Journal of Cancer 1999 79 286-292.
13. Grenman S, Engblom P, Rantanen V, Klemi P & Isola J. Cytogenetic characterization of live new ovarian carcinoma cell lines. Acta Obstetrica et Gynecologica Scandinavica 1997 76 44.
14. 125I-deoxyuridine uptake by human and chicken lymphocytes in the quantitation of mitogenic response. Journal of Immunological Methods 1974 6 73-82.
15. Smith C & Williams G. Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature 1989 337 181-184.
16. Andrews N & Faller D. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Research 1991 19 249.
17. 1) inhibits growth of a human ovarian carcinoma cell line (OVCCR1) and is expressed in human ovarian tumors. International Journal of Cancer 1992 52 766-770.
18. Kost E, Herzog T, Adler L, Williams S & Mutch D. The role of tumor necrosis factor receptors in tumor necrosis factor-α-mediated cytolysis of ovarian cancer cell lines. American Journal of Obstetrics and Gynecology 1996 174 145-153.
19. Balkwill F, Ward B, Moodie E & Fiers W. Therapeutic potential of tumor necrosis factor-α and γ-interferon in experimental human ovarian cancer. Cancer Research 1987 47 4755-4758.
20. Chaturvedi M, LaPushin R & Aggarwal B. Tumor necrosis factor and lymphotoxin. Journal of Biological Chemistry 1994 269 14575-14583.
21. Seppänen M, Henttinen T, Lin L, Punnonen J, Grenman S, Punnonen R et al. Inhibitory effect of cytokines on ovarian and endometrial carcinoma cells in vitro with special reference to induction of specific transcriptional regulators. Oncology Research 1998 10 575-589.
22. Baldwin A. The NF-κB and IκB proteins: new discoveries and insights. Annual Review of Immunology 1996 14 649-681.
23. Grimm S & Bauerle P. The inducible transcription factor NP-κB: structure-function relationship of protein subunits. Biochemical Journal 1993 290 297-308.
24. 1 on a human ovarian cancer cell line (HOC-7). Journal of Cellular Physiology 1992 151 13-22.
25. 1 in a human ovarian carcinoma cell line. Experimental Cell Research 1995 216 13-20.
26. Zhu Y-M. Bradbury D & Russell N. Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. British Journal of Cancer 1994 69 468-472.
27. Eliopoulos A, Kerr D, Herod J, Hodkings L, Krajewski S, Reed J et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995 11 1217-1228.
28. Provencher D, Lounis H, Fink D, Drouin P & Mes-Masson A. Discordance in p53 mutations when comparing ascites and solid tumors from patients with serous ovarian cancer. Tumour Biology 1997 18 167-174.
29. Rantanen V, Grenman S, Kurvinen K, Hietanen S, Raitanen M & Syrjänen S. p53 mutations and presence of HPV DNA do not correlate with radiosensitivity of gynecological cancer cell lines. Gynecologic Oncology 1998 71 352-358.
30. Mayo M, Wang C, Cogswell P, Rogers-Graham K, Lowe S. Der C et al. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 1997 278 1812-1815.
31. Bours V, Dejardin E, Goujon-Letawe F, Merville M & Castronovo V. The NF-κB transcription factor and cancer: high expression of NF-κB and IκB-related proteins in tumor cell lines. Biochemical Pharmacology 1994 47 145-149.
32. Nakshatri H, Bhat-Nakshatri P, Martin D, Goulet R Jr & Sledge G Jr. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Molecular and Cellular Biology 1997 17 3629-3639.
33. Sovak M, Bellas R, Kim D, Zanieski G, Rogers A, Traish A et al. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. Journal of Clinical Investigations 1997 100 2952-2960.
34. Angel P & Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochimica et Biophysica Acta 1991 1072 129-157.
35. 1 is mediated by the AP-1 complex. Molecular and Cellular Biology 1990 10 1492-1497.
36. Dixit V, Marks R, Sarma V & Prochowniks E. The antimitogenic action of tumor necrosis factor is associated with increased AP-1/c-jun proto-oncogene transcription. Journal of Biological Chemistry 1989 264 16905-16909.
37. Powell C, Horuchi T, Kao M-S & Collins J. Interferon alfa activates a lytic mechanism in ovarian and cervical carcinoma cells. American Journal of Obstetrics and Gynecology 1993 169 661-667.
38. Welander C. Use of interferon in the treatment of ovarian cancer as a single agent and in combination with cytotoxic drugs. Cancer 1987 59 617-619.
39. Massad L. Powell C, Kao M-S & Collins J. Expression of a resistance in ovarian and cervical carcinoma cells prevents their lysis by γ-interferon. Cancer Research 1990 50 4923-4928.
40. Vihko KK, Seppänen M, Henttinen T, Punnonen J, Grenman S & Punnonen R. Regulation of UM-SCV-1A and UM-SCV-6 vulvar carcinoma cell proliferation by cytokines. Cancer Immunology Immunotherapy 1997 43 368-374.
41. Lewis G, Aggarwal B, Eessalu T, Sugarman B & Shepard M. Modulation of the growth of transformed cells by human tumor necrosis factor-α and interferon-γ. Cancer Research 1987 47 5382-5385.
42. Wright K, Kollos G, Westwick J & Ward S. Cytokines-induced apoptosis in epithelial HT-29 cells is dependent on nitric oxide formation. Evidence for an interleukin-13-driven phosphatidylinositol 3-kinase-dependent survival mechanism. Journal of Biological Chemistry 1999 274 17193-17201.
43. Suarez-Pcstana E, Bjoklund G, Larsson R, Nygren P, Nilsson K & Bergh J. Effects of interferons and tumour necrosis factor-alpha on human lung cancer cell lines and the development of an interferon-resistant lung cancer cell line. Acta Oncologica 1996 35 473-478.
44. Salmon S & Liu R. Effects of granulocyte-macrophage colony-stimulating factor on in vitro growth of human solid tumors. Journal of Clinical Oncology 1989 7 1346-1350.
45. Dranoff G, Jaffee K, Lazemby A, Golumbek P, Levitsky H, Brose K et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proceedings of the National Academy of Sciences of the VSA 1993 90 3539-3543.
46. Steward W. Granulocyte and granulocyte-macrophage colony-stimulating factors. Lancet 1993 342 153-157.
47. Mule J, McIntosh J, Jablons D & Rosenberg S. Antitumor activity of recombinant interleukin 6 in mice. Journal of Experimental Medicine 1990 171 629-636.
48. Chen L, Shulman L & Revel M. IL-6 receptors and sensitivity to growth inhibition by IL-6 in clones of human breast carcinoma cells. Journal of Biological Regulators and Homeastatic Agents 1991 5125-136.
49. Wu S, Rodabaugh K, Martinez-Maza O, Watson J, Silberstein D, Boyer C et al. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-α. American Journal of Obstetrics and Gynecology 1992 166 997-1007.